Q: Could you summarize the magnitude of benefit seen with Dato-DXd compared to chemotherapy in this first-line mTNBC population and comment on how clinically meaningful this is for practice?
Rebecca Dent, MD: As we know, patients with metastatic…
Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC
